Navigation Links
VaxGen Reports Financial Update
Date:3/6/2008

ion shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

VaxGen, Raven and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of VaxGen in connection with the merger transaction. Information regarding the special interests of these directors and executive officers in the merger transaction is included in the proxy statement/prospectus described above. Additional information regarding the directors and executive officers of VaxGen is also included in VaxGen's definitive proxy statement for its 2007 Annual Meeting of Stockholders which was filed with the SEC on November 21, 2007 and its Annual Report on Form 10-K for the year ended December 31, 2006, which was filed with the SEC on August 30, 2007. These documents are available free of charge at the SEC's web site at http://www.sec.gov and from Investor Relations at VaxGen as described above.

- FINANCIAL CHARTS TO FOLLOW -

Selected Consolidated Financial Information

CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share data)

(Unaudited)

Year Ended December 31,

2007 2006

Revenues:

Research contracts, grants and other services $5,011 $13,205

Related party ser
'/>"/>

SOURCE VaxGen Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. VaxGen to Present at the 10th Annual BIO CEO and Investor Conference
2. VaxGen and Raven Announce Form S4 Registration Statement Declared Effective
3. VaxGen Stockholders Overwhelmingly Approve Reverse Split Proposal
4. VaxGen Common Stock Expected to Qualify for Quotation on OTC Bulletin Board
5. VaxGen Addresses MPM Claims in Letter to Stockholders
6. VaxGen Files Last Outstanding Periodic Report With SEC
7. Jack Anthony to Resign From VaxGens Board After Accepting CEO Position at Osprey Pharmaceuticals
8. VaxGen Files First Quarter 2007 Financials
9. VaxGen Further Restructures to Preserve Cash as It Pursues Strategic Initiatives
10. VaxGen Files 2006 Financial Statements and Provides Cash Update
11. EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22, 2015 Diagenode, Inc., a ... the Bioruptor® and complete solutions for epigenetics research, ... immunoprecipitation, alleviating the need for manual processing. The ... for ChIP of histones or transcription factors and ...
(Date:1/22/2015)...  Derma Sciences, Inc. (Nasdaq: DSCI ), ... care, announces that AMNIOEXCEL® and AMNIOMATRIX®, amniotic allografts ... the Premier, Inc. Regenerative Skin Grafting contract portfolio. ... and AMNIOMATRIX® product lines, which continue to be ...
(Date:12/24/2014)...   BioLife Solutions , Inc. (NASDAQ: BLFS ), ... hypothermic storage and cryopreservation freeze media ... tissues  ("BioLife" or the "Company"), today announced that it will ... 2015 (the "Annual Meeting"). Because the expected date ...
(Date:12/24/2014)... 2014 On Friday, December 19, 2014, ... and Continuing Resolution Appropriations Act of 2015, which for ... receive funding through the Congressionally Directed Medical Research Programs ... Hydrocephalus Association (HA), working in conjunction with its allies ...
Breaking Biology Technology:Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5BioLife Solutions Sets Date for Annual Meeting of Stockholders 2Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2
... the National Institute of Standards and Technology (NIST) have ... go through an intersection while keeping their cool. Ten ... fact. The demonstration, described in a forthcoming paper in ... scaling up trap technology to build a large-scale quantum ...
... April 8 The University of Maryland today announces ... Business Plan Competition.Finalists present their ideas to a panel of new ... the University of Maryland, College Park . The competition is ... Information Technology Category include: , , ...
... DNA sequencing technology company, announced a definitive agreement ... investment in the company. Prompting its decision was ... reversible terminator chemistry, Lightning Terminators (TM), for ... chemistry as reagent kits to the market as ...
Cached Biology Technology:X marks the spot: Ions coldly go through NIST trap junction 2University of Maryland Announces Finalists for $75K Business Plan Competition 2University of Maryland Announces Finalists for $75K Business Plan Competition 3University of Maryland Announces Finalists for $75K Business Plan Competition 4University of Maryland Announces Finalists for $75K Business Plan Competition 5University of Maryland Announces Finalists for $75K Business Plan Competition 6SeqWright to Invest in LaserGen's Novel Lightning Terminators(TM) 2
(Date:1/22/2015)... 22, 2015 Research and Markets ( ... "Global Wearable Technologies Market and Applications, Opportunities, ... and Forecast 2014-2020" report to their offering. ... devices that can be worn on the user,s ...
(Date:12/22/2014)... Research and Markets ( http://www.researchandmarkets.com/research/fx4bg3/the_global ) ... Global Watermarking and Fingerprinting Markets" report to ... This insight provides an overview ... markets. Watermarking aims to control and monitor piracy ...
(Date:12/19/2014)... LAS VEGAS , Dec. 18, 2014   LaunchKey ... built for the post-password and Internet of Things era, ... seed funding. The venture round was led by Metamorphic ... Capital, Rimrock Venture Partners, VegasTechFund, and others.  LaunchKey has ...
Breaking Biology News(10 mins):Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2The Global Watermarking and Fingerprinting Markets 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3
... from also becoming infected with hepatitis, researchers argue in a ... put people at higher risk of contracting HIV sharing ... also raise their risk of getting hepatitis B or ... be deadly. The study, which included all registered cases ...
... diseases like Alzheimer,s and Parkinson,s endogenous proteins accumulate in ... cells. These deposits, which consist of abnormally formed proteins, ... brain, thereby contributing to the development of the illness. ... and the US shows that certain protein particles are ...
... the genetic material of those animal and plant ... at the Institute of Molecular Genetics, Genetic Security ... (JGU) have developed a novel screening procedure that ... plant, and microbial substances present in foodstuffs. For ...
Cached Biology News:HIV sufferers need hepatitis safeguards 2Transmission routes of spreading protein particles 2New DNA test identifies ingredients in foods 2
RAB32, member RAS oncogene family, mRNA (cDNA clone MGC:13500 IMAGE:4280407), complete cds...
Request Info...
Phospho-TAO2 (S181) Affinity Purified Polyclonal Ab Protein Family: Other Intracellular Kinases...
PEG 8000 is used in the precipitation of phage, isolation of plasmid DNA and the enhancement of blunt-ended ligation reactions....
Biology Products: